Gilead’s tie up with generic cos could not tackle HIV problem
US pharma large Gilead’s partnership with home generic producers, aimed toward enhancing entry to inexpensive lenacapavir—a groundbreaking remedy for HIV prevention—could fall quick in addressing the wants of high-incidence growing
